Enlivex completes enrollment for GVHD in transplant

September 2011
Worldwide Biotech;Sep2011, Vol. 23 Issue 9, p5
Trade Publication
The article reports on biotechnology firm Enlivex Therapeutics' completion of enrollment for its Phase I/II clinical trials for the treatment of graft versus host disease (GVHD) in bone marrow transplant patients in Israel. The company is expecting to recruit about 12 patients in the next three months of 2011. The trial is also relevant to patients with autoimmune diseases. Comments from Enlivex chief executive officers (CEO) Alon Moran are provided.


Related Articles

  • Response as an end point in treatment trials for acute GVHD. Pavletic, S Z // Bone Marrow Transplantation;Feb2012, Vol. 47 Issue 2, p161 

    The author argues on that the studies have provided data that suggest day 28 as a suitable time point in measuring the response to first-line therapy in clinical trials for acute graft versus host disease (GVHD). The author stresses that the studies support the expert panel endorsement of day 28...

  • Enhanced formation of neutrophil extracellular traps in patients with graft versus host disease. Qiao, Jianlin; Zhu, Feng; Liu, Yun; Li, Yuanyuan; Li, Pan; Li, Depeng; Li, Zhenyu; Xu, Kailin; Zeng, Lingyu // Annals of Hematology;Dec2015, Vol. 94 Issue 12, p2081 

    A letter to the editor is presented from doctors discussing a study conducted to evaluate surrogate parameters of neutrophil extracellular traps (NETs) formation in patients with acute graft versus host disease (aGHVD).

  • Erratum to: Impact of clinical pharmacist-based parenteral nutrition service for bone marrow transplantation patients: a randomized clinical trial. Mousavi, Maryam; Hayatshahi, Alireza; Sarayani, Amir; Hadjibabaie, Molouk; Javadi, Mohammadreza; Torkamandi, Hassan; Gholami, Kheirollah; Ghavamzadeh, Ardeshir // Supportive Care in Cancer;Dec2013, Vol. 21 Issue 12, p3449 

    A correction to the article "Impact of clinical pharmacist-based parenteral nutrition service for bone marrow transplantation patients: a randomized clinical trial" that was published in the September 21, 2013 issue is presented.

  • Alder Gets $38M Series D for Pipeline as BMS Carries Lead. Morrison, Trista // BioWorld Today;4/20/2012, Vol. 23 Issue 77, p1 

    The article reports that Alder BioPharmaceuticals Inc. has raised 38 million U.S. dollars in Series D financing. Alder plans to use the proceeds to support a variety of internal clinical programs. The company is conducting Phase II trials with the IL-6-targeted antibody in acute graft-vs.-host...

  • Family's public plea for dying son helps speed FDA, Chimerix launch of pilot trial. Rosenberg, Ronald // CenterWatch Weekly;3/24/2014, Vol. 18 Issue 12, p1 

    The article reports on the launch of a clinical trial for brincidofovir, an antiviral drug for patients with adenovirus infections and comprised immune systems, by Chimerix Inc. in collaboration with the U.S. Food and Drug Administration (FDA) after the public plea of the family of Josh Hardy,...

  • Osiris Targets GVHD With Stem Cell Therapy.  // Bioworld Week;10/22/2007, Vol. 15 Issue 43, p5 

    The article reports that Osiris Therapeutics Inc. is moving forward with a Phase III pivotal trial of its mesenchymal stem cell therapy Prochymal following the success of its Phase II trial in the U.S. The Prochymal is believed to be the first-line agent to treat acute graft-versus-host disease...

  • Allogeneic clonal mesenchymal stem cell therapy for refractory graft-versus-host disease to standard treatment: a phase I study. Hyeon Gyu Yi; Seung-Ah Yahng; Inho Kim; Je-Hwan Lee; Chang-Ki Min; Jun Hyung Kim; Chul Soo Kim; Sun U. Song // Korean Journal of Physiology & Pharmacology;2016, Vol. 20 Issue 1, p63 

    Severe graft-versus-host disease (GVHD) is an often lethal complication of allogeneic hematopoietic stem cell transplantation (HSCT). The safety of clinicalgrade mesenchymal stem cells (MSCs) has been validated, but mixed results have been obtained due to heterogeneity of the MSCs. In this phase...

  • Immune modulation and chronic graft-versus-host disease. Soiffer, R. J. // Bone Marrow Transplantation;Aug2008 Supplement, Vol. 42, pS66 

    As more and more patients undergoing allogeneic hematopoietic SCT (HSCT) survive the early post-transplant period, the number of individuals at risk for chronic GVHD has grown. Treatment for established cGVHD remains unsatisfactory. No experimental agent has demonstrated superiority to steroids...

  • Soligenix gets $388,000 NCI SBIR supporting a Phase 2 Trial of orBec as chronic GI GvHD treatment.  // Transplant News;Sep2012, p9 

    The article announces that Soligenix, Inc., Princeton, New Jersey, has been awarded the National Cancer Institute (NCI) Small Business Innovation Research(SBIR) grant.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics